NPTE-PT Study Guide — 2026 Edition

The cardiovascular and pulmonary systems account for 22–27 scored items on the NPTE-PT — one of the largest system domains on the 2024 FSBPT test content outline^[1]. On an examination of 225 questions delivered in five 45-question sections over five hours, with 180 scored items and 45 unscored pretest items, a passing standard of a scaled score of 600, and no penalty for wrong answers^[2], a domain this size can decide a candidate's result. The outline divides the domain into examination, foundations, and interventions^[1], and this chapter follows that division exactly. Each section below runs the same pattern: the concept, why it matters, how the exam actually tests it, and the trap that catches candidates who know just enough to pick the wrong answer.

Examination: tests and measures, including outcome measures

In this domain, examination begins with the vital signs — and the most testable of them is blood pressure. A reading has two numbers because it captures two different moments of the cardiac cycle: systolic pressure is the pressure in the arteries when the heart beats, and diastolic pressure is the pressure when the heart rests between beats^[3]. The categories the exam expects candidates to know are normal below 120/80; elevated from 120–129 with diastolic below 80; Stage 1 hypertension at 130–139 or 80–89; Stage 2 hypertension at or above 140 or 90; and hypertensive emergency above 180 and/or above 120^[3]. Note the "or" in the Stage 1 and Stage 2 definitions: either number reaching the threshold puts the reading in that category. And note the boundary the exam loves to probe: a physical therapist measures and monitors blood pressure, but only a medical professional confirms a diagnosis of hypertension^[3]. A reading in a hypertension range is a finding to document, track, and communicate — not a diagnosis to announce.

Why it matters: blood pressure questions are the purest test of whether a candidate reads both numbers and applies the category boundaries. How it is tested: a vignette gives a resting reading — say 142/88 — and asks for the category or the next step. The trap is the near-boundary reading. A systolic of 128 with a diastolic of 76 sits in the elevated category (120–129 with diastolic under 80), not in Stage 1 and not in the normal range; a systolic of 142 reaches the Stage 2 threshold on its own, because either number qualifying is enough^[3]. Candidates who remember only "140/90" as a single paired number miss readings where one number crosses a threshold while the other does not.

Outcome measures belong to this category by outline name^[1], and in the cardiopulmonary examination the outcomes that matter are the patient's response to activity: blood pressure, symptoms, and functional tolerance tracked across the episode of care. One subtlety the exam can exploit is that medications alter the measures themselves. NSAIDs elevate blood pressure^[4], so a patient taking a daily NSAID may show higher readings that reflect the drug's effect rather than a change in the underlying cardiovascular condition. The candidate who treats every elevated reading as a disease signal — and the one who ignores the medication list when interpreting vital signs — both get this wrong. The examination is never just the numbers; it is the numbers read against the patient's pharmacology.

Functional capacity testing belongs to examination under outcome measures^[1], and the test the exam names is the six-minute walk test. The 6MWT is widely used to assess functional exercise capacity — the overall cardiopulmonary reserve — of patients with cardiac and pulmonary diseases, including heart failure, pulmonary hypertension, COPD, and interstitial lung disease^[5]. The procedure is simple: the individual walks as far as possible over 6 minutes on a hard, flat surface, and the primary measurement is the distance walked — the 6-minute walk distance (6MWD)^[5]. The standardized course is a 30-meter hallway, because shorter courses force more turns; a treadmill is not recommended, since it produces a significantly lower distance than the standard hallway method^[5]. The testable protocol details: the ATS issued practical guidelines with scripted instructions and standardized phrases of encouragement, updated in a 2014 ERS/ATS technical standard^[5]; heart rate and perceived dyspnea (Borg scale) are measured at the beginning and end of the test, with arterial oxygen saturation by pulse oximetry measured at both ends or continuously^[5]. The trap is calling the 6MWT a maximal test — the sources frame it as a test of functional exercise capacity, distinct from peak exercise testing^[5].

Anatomy and physiology as related to tests and measures

Every cardiopulmonary test or measure is a window into pump function or gas exchange, and the exam rewards candidates who connect the finding to the mechanism. Heart failure is defined as a state in which the heart does not pump enough blood to meet the body's needs^[6]. The name misleads: the heart has not stopped. Because the pump under-delivers, the clinical picture is fatigue, shortness of breath, and fluid buildup — in the lower body, the abdomen, and the neck veins^[6]. That distribution of edema is itself a test finding: swelling in the ankles with visible neck-vein fullness points toward the failing pump.

COPD works through a different mechanism. Airway and lung damage produce inflammation that blocks airflow and makes breathing difficult; the disease is progressive and tends to worsen over time^[7]. Its two classic patterns are anatomically distinct: emphysema is damage to the walls of the alveoli, while chronic bronchitis is irritation of the airway lining with thick mucus production and a productive cough^[7]. The exam tests this distinction relentlessly. Alveolar wall damage and mucus-plugged airways are not interchangeable, and a candidate who treats "COPD" as a single undifferentiated entity will confuse which finding belongs to which pattern.

How it is tested: a vignette describes a patient — dyspnea plus ankle edema and abdominal fullness, or dyspnea plus a daily productive cough — and asks which condition the findings support. The trap is the shared symptom. Shortness of breath appears in both heart failure and COPD, so dyspnea alone differentiates nothing^{[6, 7]}. The discriminating findings are the clusters around it: fluid where it should not be points to the pump; mucus coming up points to the airways.

Movement analysis as related to the cardiovascular and pulmonary systems

Movement analysis in this domain means reading the body's response to activity. In heart failure, fatigue and dyspnea appear during the ordinary demands of daily life because the pump cannot meet the body's needs^[6]. In COPD, exertion unmasks the airflow blockage: activity raises the demand for gas exchange that damaged airways and alveoli cannot supply, and breathing becomes difficult^[7]. The therapist watches how quickly symptoms appear, how they limit the task, and how the patient recovers.

Why it matters: the exam frequently presents a patient who fatigues early during gait training or a functional task and asks what the finding means. The trap is attributing every activity limitation to deconditioning or to the orthopedic diagnosis on the referral. When the limitation pattern is fatigue and breathlessness disproportionate to the musculoskeletal problem — or a patient whose COPD is progressive and worsening^[7] — the cardiopulmonary system is driving the movement problem, and the plan of care must account for it. A second trap is prognosis blindness: COPD worsens over time^[7], so a movement analysis that assumes a stable baseline will misjudge the patient's trajectory. The expected course shapes the goals.

Foundations: diseases, conditions, and pathophysiology, including prognosis

Heart failure affects more than 6 million adults in the United States^[6]. Its pathophysiology is pump failure: the heart does not move enough blood for the body's needs, producing fatigue, dyspnea, and fluid accumulation in the lower body, abdomen, and neck^[6]. There is no cure; management combines lifestyle changes, medicines, devices, and procedures, with lower sodium intake, a healthy weight, and cardiac rehabilitation as recognized components^[6]. For prognosis and the plan of care, one fact carries special weight: heart failure can damage the liver and kidneys^[6]. The disease is systemic, not just cardiac, and the plan of care is built around limited physiologic reserve.

COPD affects more than 14 million US adults and ranks as the sixth leading cause of death in the United States^[7]. The pathophysiology is airway and lung damage with inflammation that blocks airflow^[7]. Smoking is the main cause in high-income countries, and alpha-1 antitrypsin deficiency can also cause the disease^[7]. Two facts define its prognosis: it is progressive and tends to worsen, and there is no cure^[7]. What can change the course is behavior and medical management — quitting smoking helps, and oxygen therapy, pulmonary rehabilitation, and medicines for complications are the treatment pillars^[7]. The exam's favorite trap here is the cure claim: pulmonary rehabilitation is a genuine treatment that improves function, but the source is explicit that COPD has no cure^[7]. "Treatment" and "cure" are different words, and the exam separates candidates who notice.

Hypertension completes the foundations triad. Its categories are the testable core: normal below 120/80, elevated 120–129 with diastolic below 80, Stage 1 at 130–139 or 80–89, Stage 2 at or above 140 or 90, hypertensive emergency above 180 and/or above 120^[3]. The foundational point for the plan of care is scope: measuring blood pressure is squarely within the therapist's examination, but confirming a hypertension diagnosis belongs to a medical professional^[3]. The therapist's role is surveillance and communication — trending the numbers, recognizing when they cross into emergency territory, and referring appropriately.

Nonpharmacological medical management

Beyond drugs, both flagship conditions in this domain have recognized non-drug medical management that the therapist must understand, because patients arrive already receiving it. Heart failure management includes lifestyle changes, devices, and procedures alongside medicines; specifically, lower sodium intake, maintaining a healthy weight, and cardiac rehabilitation may be recommended^[6]. When a patient with heart failure is enrolled in cardiac rehabilitation, that program is part of the medical management of the disease — the therapist's plan of care coordinates with it rather than duplicating or contradicting it.

COPD's non-drug management includes oxygen therapy and pulmonary rehabilitation, with medicines reserved for complications^[7]. The distinction matters for the exam: oxygen therapy and pulmonary rehabilitation are disease management, while quitting smoking is the behavioral intervention that helps^[7]. A candidate who files pulmonary rehabilitation under "cures COPD" has confused a management pillar with a prognosis — the disease remains progressive and incurable^[7].

How it is tested: a vignette names the patient's current medical management — cardiac rehabilitation enrollment, home oxygen — and asks what the therapist should do with that information. The trap is treating medical management as background trivia. It defines the context in which every PT intervention is delivered^{[6, 7]}.

Imaging and laboratory workup

Imaging and laboratory studies are the objective backbone of cardiopulmonary diagnosis^[1]. For heart failure, the exam-relevant workup includes blood tests for brain natriuretic peptide (BNP), which rises during heart failure, the electrocardiogram (EKG/ECG), and echocardiography — which measures the ejection fraction, the percent of blood in the left ventricle pumped out with each heartbeat — with cardiac CT or MRI and stress testing rounding out the diagnostic options^[8]. For COPD, the main lung function test is spirometry: the patient breathes in deeply and blows as hard as possible into a tube connected to a machine, which measures how much air is blown out and how fast — simple, noninvasive, and able to detect COPD before symptoms become severe^[9]. Supporting COPD studies include chest X-ray, chest CT, and blood oxygen saturation^[9]. The exam's trap is matching the wrong test to the disease: BNP and ejection fraction belong to the heart failure workup; spirometry belongs to COPD^{[8, 9]}.

Sources cited in this excerpt

1. NPTE-PT Test Content Outline, effective January 2024. Federation of State Boards of Physical Therapy (FSBPT), effective January 2024. https://www.fsbpt.org/Portals/0/documents/free-resources/2024-PT-Test-Content-Outline-Bullets.pdf
2. National Physical Therapy Examination (NPTE) Candidate Handbook — For the Physical Therapist (PT) and Physical Therapist Assistant (PTA) Exams. Federation of State Boards of Physical Therapy (FSBPT), Version 2025.02. https://fsbpt.org/Portals/0/documents/free-resources/NPTE_Candidate_Handbook.pdf
3. Understanding Blood Pressure Readings. American Heart Association, no date shown on page. https://heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings
4. NSAID / corticosteroid / anticoagulant facts (AAPM&R NSAID adverse-effects table; Merck Manual Consumer Version: Bruising and Bleeding; Rheumatoid Arthritis). Merck & Co., Inc. (Merck Manual Consumer Version), no date stated on page. https://www.merckmanuals.com/home/bone-joint-and-muscle-disorders/joint-disorders/rheumatoid-arthritis-ra
5. Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis (six-minute walk test procedure summary). Peer-reviewed literature (summarizing 2002 ATS guidelines and 2014 ERS/ATS technical standard), 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6291931/
6. Heart Failure — What Is Heart Failure? + Treatment | NHLBI, NIH. National Heart, Lung, and Blood Institute (NHLBI), NIH, treatment page last updated March 24, 2022. https://www.nhlbi.nih.gov/health/heart-failure
7. COPD — What Is COPD? | NHLBI, NIH. National Heart, Lung, and Blood Institute (NHLBI), NIH, no date shown on page. https://www.nhlbi.nih.gov/health/copd
8. Heart Failure - Diagnosis. National Heart, Lung, and Blood Institute (NHLBI), NIH, Last updated March 24, 2022. https://www.nhlbi.nih.gov/health/heart-failure/diagnosis
9. COPD National Action Plan. National Heart, Lung, and Blood Institute (NHLBI) / Centers for Disease Control and Prevention (CDC), May 22, 2017. https://nhlbi.nih.gov/sites/default/files/media/docs/COPD National Action Plan 508_0.pdf